326 related articles for article (PubMed ID: 30324224)
1. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
Zhuang Y; Chen D; Sharma A; Xu Z
AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.
Putnam WS; Prabhu S; Zheng Y; Subramanyam M; Wang YM
Trends Biotechnol; 2010 Oct; 28(10):509-16. PubMed ID: 20691488
[TBL] [Abstract][Full Text] [Related]
3. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
[TBL] [Abstract][Full Text] [Related]
4. Patient-centric Comparability Assessment of Biopharmaceuticals.
Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
[TBL] [Abstract][Full Text] [Related]
5. A new roadmap for biopharmaceutical drug product development: Integrating development, validation, and quality by design.
Martin-Moe S; Lim FJ; Wong RL; Sreedhara A; Sundaram J; Sane SU
J Pharm Sci; 2011 Aug; 100(8):3031-3043. PubMed ID: 21425164
[TBL] [Abstract][Full Text] [Related]
6. A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment.
Li Z; Du X; Wang YC
Pharm Res; 2024 Jan; 41(1):13-27. PubMed ID: 37910341
[TBL] [Abstract][Full Text] [Related]
7. Analytical comparability study of recombinant monoclonal antibody therapeutics.
Ambrogelly A; Gozo S; Katiyar A; Dellatore S; Kune Y; Bhat R; Sun J; Li N; Wang D; Nowak C; Neill A; Ponniah G; King C; Mason B; Beck A; Liu H
MAbs; 2018; 10(4):513-538. PubMed ID: 29513619
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceutical quality by design: product and process development, understanding, and control.
Yu LX
Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
[TBL] [Abstract][Full Text] [Related]
9. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
Farid SS; Baron M; Stamatis C; Nie W; Coffman J
MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
[TBL] [Abstract][Full Text] [Related]
10. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality.
Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF
PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321
[TBL] [Abstract][Full Text] [Related]
11. Risk-Based Approach for Analytical Comparability and Comparability Protocols.
Iyer KR; Lequeux I
PDA J Pharm Sci Technol; 2020; 74(5):563-570. PubMed ID: 32295861
[TBL] [Abstract][Full Text] [Related]
12. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.
Vezér B; Buzás Z; Sebeszta M; Zrubka Z
Curr Med Res Opin; 2016 May; 32(5):829-34. PubMed ID: 26808864
[TBL] [Abstract][Full Text] [Related]
13. Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
Kretsinger J; Frantz N; Hart SA; Kelley WP; Kitchen B; Novick S; Rellahan B; Stranges D; Stroop CJM; Yin P; Gastens MH
J Pharm Sci; 2019 Apr; 108(4):1442-1452. PubMed ID: 30528942
[TBL] [Abstract][Full Text] [Related]
14. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies.
Ishii-Watabe A; Kuwabara T
Drug Metab Pharmacokinet; 2019 Feb; 34(1):64-70. PubMed ID: 30600193
[TBL] [Abstract][Full Text] [Related]
15. [The Identification of Critical Quality Attributes (CQAs) for the Development of Antibody Drugs].
Saitoh S
Yakugaku Zasshi; 2018; 138(12):1475-1481. PubMed ID: 30504661
[TBL] [Abstract][Full Text] [Related]
16. Comparability Considerations and Challenges for Expedited Development Programs for Biological Products.
Schrieber SJ; Putnam WS; Chow ECY; Cieslak J; Zhuang Y; Martin SW; Hanson P; Maggio F; Rosado LAR
Drugs R D; 2020 Dec; 20(4):301-306. PubMed ID: 32914381
[TBL] [Abstract][Full Text] [Related]
17. Determination of critical quality attributes for monoclonal antibodies using quality by design principles.
Alt N; Zhang TY; Motchnik P; Taticek R; Quarmby V; Schlothauer T; Beck H; Emrich T; Harris RJ
Biologicals; 2016 Sep; 44(5):291-305. PubMed ID: 27461239
[TBL] [Abstract][Full Text] [Related]
18. Comparability assessments of process and product changes made during development of two different monoclonal antibodies.
Lubiniecki A; Volkin DB; Federici M; Bond MD; Nedved ML; Hendricks L; Mehndiratta P; Bruner M; Burman S; Dalmonte P; Kline J; Ni A; Panek ME; Pikounis B; Powers G; Vafa O; Siegel R
Biologicals; 2011 Jan; 39(1):9-22. PubMed ID: 20888784
[TBL] [Abstract][Full Text] [Related]
19. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
[TBL] [Abstract][Full Text] [Related]
20. Current and future issues in the manufacturing and development of monoclonal antibodies.
Kozlowski S; Swann P
Adv Drug Deliv Rev; 2006 Aug; 58(5-6):707-22. PubMed ID: 16828921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
